<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246310</url>
  </required_header>
  <id_info>
    <org_study_id>agunco7/2010</org_study_id>
    <nct_id>NCT01246310</nct_id>
  </id_info>
  <brief_title>Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients</brief_title>
  <official_title>Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGUNCO Obstetrics and Gynecology Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Clinico Colle Cesarano Tivoli Rome Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AGUNCO Obstetrics and Gynecology Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is one of the most common reproductive disorders affecting
      5-10% of women of reproductive age. Beside impairments on reproductive functions
      (oligomenorrhea/amenorrhea), it also affects metabolism (insulin resistance, type 2 diabetes
      mellitus and cardiovascular risk) and psychology (increased anxiety, depression and eating
      disorders). Recently, several studies have shown that there is an increased risk of mood
      disorders in women with PCOS, with major depression and bipolar disorder as the most frequent
      diagnosis.

      Myo-inositol is classified as a member of the vitamin B complex and it works as a second
      messenger system of several neurotransmitter receptors; furthermore, inositol, when
      administrated at pharmacological doses, crosses the blood-brain barrier.

      Studies from the 90s showed that inositol, alone or in combination with other antidepressant
      drugs (mainly serotonin reuptake inhibitors), is able to induce improvement of the Hamilton
      depression rating Scale.

      Recently, inositol has been proposed as treatment to improve clinical, metabolic and
      endocrinal status in PCOS patients. Administration of myo-inositol to PCOs patients resulted
      in several beneficial effects, such as decrease of circulating insulin and serum total
      testosterone as well as a restored ovulation.

      In this proposed study, the investigators aim to evaluate in a double blind randomized trial
      whether inositol alone has beneficial effects on mental health disorders associated with
      PCOs. In particular, 60 women in reproductive age that will be diagnosed of PCOs, according
      to Rotterdam 2003 criteria, will be recruited and randomly assigned to the inositol or
      placebo group. Both groups will go through ultrasonic evaluation of the ovaries and serum
      hormonal levels (FSH, LH, testosterone, estradiol and insulin) will be evaluated.
      Furthermore, with the help of psychiatrics, patients will be interviewed in order to test the
      presence of any mental health disorders using validated tests such as: Hamilton Anxiety Scale
      (HAM-A), Hamilton Rating Scale for Depression (HAM-D), Health Assessment Questionnaire (HAQ),
      Short Form of Mc Gill Pain Questionnaire (SF-MPQ).

      Women assigned to the inositol group will receive 12g of inositol during the day in three
      different administrations for a period of 4weeks.

      At the end of treatment period patients will be interviewed by psychiatrics and will go
      through ultrasonic evaluation of the ovaries and hormonal levels will be tested
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for depression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Anxiety Scale</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Health assessment Questionnaire</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Short form of Mc Gill Pain Questionnaire</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depression</condition>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Inositol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inositol</intervention_name>
    <arm_group_label>Inositol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed of PCOS according to Rotterdam 2003 criteria

        Exclusion Criteria:

          -  BMI &gt;30

          -  Pharmacological treatment in the last 3 moths

          -  Use of contraceptive pill
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vittorio Unfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AGUNCO Obstetrics and Gynecology Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Buffo Silvia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Clinico Colle Cesarano Tivoli Rome Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vittorio Unfer, MD</last_name>
    <phone>+39 0640500835</phone>
    <email>vunfer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gianfranco Carlomagno, PhD</last_name>
    <email>gianfranco.carlomagno@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Agunco</name>
      <address>
        <city>Rome</city>
        <zip>Rome</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Unfer, MD</last_name>
      <email>vunfer@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gianfranco Carlomagno, PhD</last_name>
      <email>gianfranco.carlomagno@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vittorio Unfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gianfranco Carlomagno, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.</citation>
    <PMID>19499845</PMID>
  </reference>
  <reference>
    <citation>Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 1995 May;152(5):792-4.</citation>
    <PMID>7726322</PMID>
  </reference>
  <reference>
    <citation>Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril. 2009 Jan;91(1):207-12. doi: 10.1016/j.fertnstert.2007.11.022. Epub 2008 Feb 4.</citation>
    <PMID>18249398</PMID>
  </reference>
  <reference>
    <citation>Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009 Dec;147(2):120-3. doi: 10.1016/j.ejogrb.2009.09.008. Epub 2009 Oct 2. Review.</citation>
    <PMID>19800728</PMID>
  </reference>
  <reference>
    <citation>Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010 Jun 30;8:41. doi: 10.1186/1741-7015-8-41. Review.</citation>
    <PMID>20591140</PMID>
  </reference>
  <reference>
    <citation>Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010 Oct;122(1-3):42-52. doi: 10.1016/j.jsbmb.2009.12.010. Epub 2009 Dec 28. Review.</citation>
    <PMID>20036327</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>AGUNCO Obstetrics &amp; Gynecology Center</name_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

